Aclaris Therapeutics (ACRS) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 0.68.
- Aclaris Therapeutics' Equity Ratio fell 411.63% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 411.63%. This contributed to the annual value of 0.71 for FY2024, which is 1132.99% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Equity Ratio is 0.68, which was down 411.63% from 0.7 recorded in Q2 2025.
- Aclaris Therapeutics' Equity Ratio's 5-year high stood at 0.85 during Q2 2022, with a 5-year trough of 0.68 in Q3 2025.
- Moreover, its 5-year median value for Equity Ratio was 0.78 (2022), whereas its average is 0.77.
- Per our database at Business Quant, Aclaris Therapeutics' Equity Ratio soared by 4768.92% in 2021 and then crashed by 1616.9% in 2025.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Equity Ratio stood at 0.79 in 2021, then decreased by 1.19% to 0.78 in 2022, then increased by 2.58% to 0.8 in 2023, then dropped by 11.33% to 0.71 in 2024, then dropped by 3.09% to 0.68 in 2025.
- Its last three reported values are 0.68 in Q3 2025, 0.7 for Q2 2025, and 0.73 during Q1 2025.